Jonathan Steinfeld

2.3k total citations · 1 hit paper
36 papers, 1.3k citations indexed

About

Jonathan Steinfeld is a scholar working on Rheumatology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Jonathan Steinfeld has authored 36 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Rheumatology, 19 papers in Surgery and 18 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Jonathan Steinfeld's work include Eosinophilic Disorders and Syndromes (21 papers), Eosinophilic Esophagitis (18 papers) and Asthma and respiratory diseases (15 papers). Jonathan Steinfeld is often cited by papers focused on Eosinophilic Disorders and Syndromes (21 papers), Eosinophilic Esophagitis (18 papers) and Asthma and respiratory diseases (15 papers). Jonathan Steinfeld collaborates with scholars based in United States, United Kingdom and France. Jonathan Steinfeld's co-authors include Paneez Khoury, Amy D. Klion, Praveen Akuthota, Gerald J. Gleich, Michael E. Wechsler, Steven W. Yancey, María C. Cid, Frank Moosig, Ulrich Specks and Judith C. Brown and has published in prestigious journals such as New England Journal of Medicine, Journal of Allergy and Clinical Immunology and Frontiers in Immunology.

In The Last Decade

Jonathan Steinfeld

36 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis

2017 589 citations Michael E. Wechsler, Praveen Akuthota et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jonathan Steinfeld United States	13	809	757	545	416	203	36	1.3k
JingYuan Feng United States	10	327 0.4×	161 0.2×	603 1.1×	95 0.2×	367 1.8×	11	865
Cornelis A. Verburgh Netherlands	10	386 0.5×	171 0.2×	124 0.2×	89 0.2×	106 0.5×	21	619
T. Ponge France	15	467 0.6×	364 0.5×	115 0.2×	95 0.2×	53 0.3×	48	684
Peer Aries Germany	13	374 0.5×	319 0.4×	168 0.3×	61 0.1×	148 0.7×	51	707
J Mooney United Kingdom	7	537 0.7×	357 0.5×	165 0.3×	63 0.2×	93 0.5×	11	730
Maxime Samson France	14	529 0.7×	370 0.5×	48 0.1×	51 0.1×	132 0.7×	60	727
Sara Alehashemi United States	10	350 0.4×	224 0.3×	82 0.2×	135 0.3×	124 0.6×	19	626
J. Connault France	11	280 0.3×	175 0.2×	66 0.1×	115 0.3×	47 0.2×	57	507
GSRSNK Naidu India	13	222 0.3×	166 0.2×	60 0.1×	72 0.2×	66 0.3×	66	493
Graeme McNeill Ireland	10	159 0.2×	109 0.1×	127 0.2×	93 0.2×	45 0.2×	21	538

Countries citing papers authored by Jonathan Steinfeld

Since Specialization

Citations

This map shows the geographic impact of Jonathan Steinfeld's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jonathan Steinfeld with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jonathan Steinfeld more than expected).

Fields of papers citing papers by Jonathan Steinfeld

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jonathan Steinfeld. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jonathan Steinfeld. The network helps show where Jonathan Steinfeld may publish in the future.

Co-authorship network of co-authors of Jonathan Steinfeld

This figure shows the co-authorship network connecting the top 25 collaborators of Jonathan Steinfeld. A scholar is included among the top collaborators of Jonathan Steinfeld based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jonathan Steinfeld. Jonathan Steinfeld is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Khoury, Paneez, Praveen Akuthota, Namhee Kwon, Jonathan Steinfeld, & Florence Roufosse. (2023). HES and EGPA. Mayo Clinic Proceedings. 98(7). 1054–1070. 16 indexed citations

Terrier, Benjamin, David Jayne, Bernhard Hellmich, et al.. (2023). Clinical Benefit of Mepolizumab in Eosinophilic Granulomatosis With Polyangiitis for Patients With and Without a Vasculitic Phenotype. ACR Open Rheumatology. 5(7). 354–363. 13 indexed citations

Jayne, David, Benjamin Terrier, Bernhard Hellmich, et al.. (2023). Mepolizumab has clinical benefits including oral corticosteroid sparing irrespective of baseline EGPA characteristics. ERJ Open Research. 10(1). 509–2023. 10 indexed citations

Roufosse, Florence, Joseph H. Butterfield, Jonathan Steinfeld, et al.. (2023). Mepolizumab therapy improves the most bothersome symptoms in patients with hypereosinophilic syndrome. Frontiers in Medicine. 10. 1035250–1035250. 6 indexed citations

Alfonso‐Cristancho, Rafael, et al.. (2023). The Validity of the Asthma Daytime Symptoms Diary (ADSD) and the Asthma Nighttime Symptoms Diary (ANSD) As Measures of Symptoms in Patients With Moderate-to-Severe Asthma. A3033–A3033. 1 indexed citations

Pane, Fabrizio, Guillaume Lefèvre, Namhee Kwon, et al.. (2022). Characterization of disease flares and impact of mepolizumab in patients with hypereosinophilic syndrome. Frontiers in Immunology. 13. 935996–935996. 4 indexed citations

Akuthota, Praveen, et al.. (2022). Clinical Profile and Treatment in Hypereosinophilic Syndrome Variants: A Pragmatic Review. The Journal of Allergy and Clinical Immunology In Practice. 10(8). 2125–2134. 28 indexed citations

Maltzahn, Robyn von, Linda Nelsen, Jane H. Bentley, Namhee Kwon, & Jonathan Steinfeld. (2021). PSY2 Impact of Mepolizumab on Health-Related Quality of Life in Patients With Hypereosinophilic Syndrome. Value in Health. 24. S229–S229. 1 indexed citations

Pouliquen, Isabelle, Daren Austin, Jonathan Steinfeld, & Steven W. Yancey. (2021). Justification of the Subcutaneous Mepolizumab Dose of 300 mg in Eosinophilic Granulomatosis With Polyangiitis and Hypereosinophilic Syndrome. Clinical Therapeutics. 43(7). 1278–1280. 5 indexed citations

10.

Logie, John, et al.. (2021). The increasing incidence and prevalence of hypereosinophilic syndrome in the United Kingdom. Immunity Inflammation and Disease. 9(4). 1447–1451. 12 indexed citations

11.

Roufosse, Florence, Jean‐Emmanuel Kahn, Marc E. Rothenberg, et al.. (2020). Efficacy and safety of mepolizumab in hypereosinophilic syndrome: A phase III, randomized, placebo-controlled trial. Journal of Allergy and Clinical Immunology. 146(6). 1397–1405. 111 indexed citations

12.

Benjamin, Katy, Nicole Holland‐Thomas, Linda Nelsen, et al.. (2020). Symptom assessment in hypereosinophilic syndrome: Toward development of a patient-reported outcomes tool. The Journal of Allergy and Clinical Immunology In Practice. 8(9). 3209–3212.e8. 9 indexed citations

13.

Condreay, Lynn D., Xiaoyan A. Qu, Jonathan Steinfeld, et al.. (2020). Pharmacogenetic investigation of efficacy response to mepolizumab in eosinophilic granulomatosis with polyangiitis. Rheumatology International. 40(8). 1301–1307. 3 indexed citations

14.

Gupta, Atul, Masanori Ikeda, Bob Geng, et al.. (2019). Long-term safety and pharmacodynamics of mepolizumab in children with severe asthma with an eosinophilic phenotype. Journal of Allergy and Clinical Immunology. 144(5). 1336–1342.e7. 70 indexed citations

15.

Kuang, Fei, Michael P. Fay, JeanAnne Ware, et al.. (2018). Long-Term Clinical Outcomes of High-Dose Mepolizumab Treatment for Hypereosinophilic Syndrome. The Journal of Allergy and Clinical Immunology In Practice. 6(5). 1518–1527.e5. 58 indexed citations

16.

Wechsler, Michael E., Praveen Akuthota, David Jayne, et al.. (2017). Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis. New England Journal of Medicine. 376(20). 1921–1932. 589 indexed citations breakdown →

17.

Song, Sharon, et al.. (2015). Pharmacokinetics of fluticasone propionate multidose, inhalation-driven, novel, dry powder inhaler versus a prevailing dry powder inhaler and a metered-dose inhaler. Allergy and Asthma Proceedings. 36(5). 365–371. 6 indexed citations

18.

Song, Sharon, et al.. (2015). Pharmacokinetics, Safety, and Tolerability of a New Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone Propionate Diskus ^® in Healthy Adults. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 29(2). 207–214. 5 indexed citations

19.

Rice, Jessica L., et al.. (2015). LEAP: A randomized–controlled trial of a lay-educator inpatient asthma education program. Patient Education and Counseling. 98(12). 1585–1591. 20 indexed citations

20.

Schidlow, Daniel V. & Jonathan Steinfeld. (2005). Primary Ciliary Dyskinesia (Immotile Cilia Syndrome—Kartagener Syndrome). Pediatric Pulmonology. 73(6). 131–139. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact